# Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma

> **NCT01192555** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Baylor College of Medicine** · enrollment: 11 (actual)

## Conditions studied

- Neuroblastoma

## Interventions

- **BIOLOGICAL:** Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells
- **DRUG:** Cytoxan

## Key facts

- **NCT ID:** NCT01192555
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2010-09
- **Primary completion:** 2012-07
- **Final completion:** 2026-09
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01192555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01192555, "Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT01192555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*